# Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

> **NCT00481689** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 500 (actual)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** Cipro XR (Ciprofloxacin, BAYQ3939)

## Key facts

- **NCT ID:** NCT00481689
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2009-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481689, "Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00481689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*